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Development and implementation of a pharmacist-managed 
outpatient parenteral antimicrobial therapy program 
Eun Kyoung Chung, Cole B. Beeler, Eva W. Muloma, Danielle Osterholzer, Kendra M. 
Damer and Sharon M. Erdman 
 
Abstract:  
Purpose: The development and implementation of a pharmacist-managed outpatient parenteral 
antimicrobial therapy (OPAT) program in a county teaching hospital are described.  
Summary: A pharmacist-managed OPAT program was developed and implemented at a county teaching 
hospital to provide consistent evaluation, approval, and monitoring of patients requiring OPAT for the 
treatment of infection. The developmental and implementation stages of the OPAT program included (1) 
a needs assessment, (2) the identification of resources necessary for program operation, (3) delineation of 
general OPAT program operations and activities of individual OPAT clinicians, (4) the development of 
patient selection criteria, including a plan of care algorithm, and (5) acquisition of administrative support 
to approve the program. In this program, the OPAT pharmacist plays an integral role in the management 
and oversight of OPAT patients, working under a collaborative agreement with infectious diseases 
physicians. The OPAT pharmacist assists with appropriate patient and regimen selection, confirmation of 
orders on discharge, assuring that laboratory tests for safety surveillance are performed and evaluated, 
performing routine monitoring for adverse events and line complications, and assuring the removal of the 
vascular access device upon the completion of OPAT.  
Conclusion: The OPAT program provides structured monitoring, patient follow-up, and led to 











Outpatient parenteral antimicrobial therapy (OPAT) is the practice of administering parenteral 
antimicrobial therapy in settings outside of a hospital, such as the home or other outpatient facility 
(e.g., infusion center, physician office, skilled nursing facility).1 The use of OPAT has grown 
substantially since the practice was first described in 1974. This increased use has been attributed 
to the development of antibiotics that can be administered once or twice daily, technological 
advances in vascular access and infusion devices, high OPAT acceptance by patients and 
healthcare professionals, the availability of reliable OPAT services in the community, and efforts 
to reduce overall healthcare costs.1 Additionally, as healthcare providers and institutions are 
increasingly evaluated on metrics such as quality of care and hospital length of stay, OPAT will 
likely be utilized at a higher rate. In addition, OPAT has been shown to be safe and effective for a 
wide range of infectious diseases (ID), including skin and soft tissue infections (cellulitis, 
osteomyelitis, and septic arthritis), bacteremia, endocarditis, pyelonephritis, meningitis, brain 
abscess, and intraabdominal infections.1–11 
In 2004, the Infectious Diseases Society of America (IDSA) published guidelines outlining the 
safe and effective practice of OPAT, with specific recommendations addressing (1) appropriate 
patient evaluation and selection, (2) essential elements of an OPAT program, (3) roles and 
responsibilities of individual OPAT team members, (4) appropriate selection and administration 
of antibiotics for OPAT, and (5) laboratory monitoring parameters and recommended frequencies 
according to the antimicrobial agent used.1 The IDSA guideline recommendations on appropriate 
patient and antibiotic selection for OPAT support current antimicrobial stewardship efforts 
directed at ensuring judicious and cost-effective use of antimicrobial agents.1,5 
Common models for the delivery of OPAT include the infusion center model, the self-
administration model, and the long-term care facility model.1,4,6,9,11,12 
In the infusion center model, OPAT is administered in a variety of settings (e.g., hospital clinic, 
emergency department, urgent care center, physician’s office, freestanding infusion facility). The 
primary limitation of this model is the need for frequent patient transportation to receive OPAT.  
The self-administration model involves the administration of parenteral antimicrobials by patients 
or their caregivers in the home after they have received appropriate training by a healthcare 
professional (usually a home care nurse) in infusion technique and line care. Once the patient 
displays competency with self-administration, periodic nursing visits are performed for 
surveillance laboratory monitoring, line dressing changes, and (if applicable) infection-site 
assessments. The self-administration model is typically less costly than the infusion center model 
or long-term care facility model and is associated with higher patient satisfaction because it allows 
the patient to return to the home environment and daily life activities. With this model, the patient 
must still travel for periodic clinic visits or radiographic tests; however, the frequency of travel is 
substantially less than with the infusion center model.  
The long-term care facility model involves the administration of OPAT in skilled nursing facilities, 
which may be more appropriate for patients with physical, psychological, behavioral, financial, or 
social limitations for whom home administration of OPAT is not safe or feasible. This form of 
care is more costly than the infusion center or the self-administration model, and the patient may 
still need to travel for follow-up clinic visits and radiographic tests during the course of OPAT. 
Regardless of the model of delivery of OPAT, there is the potential for the pharmacist to play an 
integral role in optimizing drug therapy and minimizing adverse effects and line complications 
associated with parenteral antimicrobial therapy.  
Pharmacist-managed ambulatory care clinics have been implemented for patients with a variety of 
disease states, including asthma, hyperlipidemia, hypertension, diabetes mellitus, human 
immunodeficiency virus infection, and hepatitis C, as well as patients requiring anticoagulation 
therapy or pharmacogenetic testing.13–20 There is evidence that clinical outcomes in patients 
receiving care within pharmacist-managed programs are either comparable14,20 or superior18,19 to 
those achieved in physician-managed programs. The increasing use of OPAT as a cost-saving 
measure provides a prime opportunity for pharmacists to become involved in this form of care. To 
date, there are a limited number of pharmacist-managed OPAT programs in the United States, and 
published data outlining their development and implementation are lacking. This report describes 
the development and implementation of a pharmacist-managed OPAT program at a county 
teaching hospital with limited resources. 
Background and OPAT program justification 
Eskenazi Health (EH, formerly Wishard Health Services) is a 316-bed safety-net hospital in 
Indianapolis, Indiana, with approximately 15,000 adult hospital admissions annually. The EH 
system also comprises a large outpatient clinic network that provides nearly 1 million clinic visits 
annually. Prior to July 2008, EH lacked a systematic or coordinated approach to the management 
of patients receiving OPAT, with many practices deviating from the recommendations set forth in 
the IDSA guidelines on OPAT. Any clinician with prescribing authority, including a resident 
physician, could order OPAT without involvement or consultation by an inpatient ID physician 
regardless of infection type, antibiotic prescribed, or duration of therapy. In many cases, this led 
to the use of OPAT without (1) a clear, established plan of care specifying the antibiotic therapy 
(including duration of therapy) and laboratory orders for monitoring, (2) designation of a physician 
to supervise the OPAT course, including therapeutic drug monitoring, adverse-effect monitoring, 
and evaluation of response to therapy, (3) a scheduled follow-up clinic appointment with a primary 
care physician or other healthcare provider to monitor response to therapy, and (4) specific 
arrangements for removal of the vascular access device on completion of OPAT. In addition, 
OPAT was occasionally used in patients with infections that could have been managed with oral 
antibiotic therapy (e.g., community-acquired pneumonia, complicated urinary tract infections), in 
patients who were not clinically stable, and in patients with suboptimal home settings or without 
responsible caregivers to assist with the administration of parenteral antibiotics. 
At EH, there is a subset of uninsured or underinsured patients who receive OPAT funded by Health 
Advantage, a charity program that provides medical care to low-income patients who are not 
eligible for other assistance programs. Prior to the development of the formal OPAT program in 
2008, this subset of patients obtained their antibiotics and supplies for administration from the EH 
inpatient pharmacy at the time of hospital discharge and then returned to the hospital periodically 
during the course of therapy to obtain medication and supplies, with the frequency of visits 
depending on the duration of therapy and the physical stability of the parenteral antibiotic used. 
Patients received instruction in the proper administration of antibiotics from inpatient pharmacists 
before discharge. Prior to 2008, i.v. antibiotics were administered without infusion pumps (often 
using the “drip-count” method), and routine weekly nurse home visits for blood collection for 
surveillance safety laboratory tests and line dressing changes were not performed. Since infusion 
pumps and state-of-the-art infusion devices were not used, suboptimal antibiotic therapy was 
occasionally selected in order to provide dosing convenience or address drug stability issues (for 
example, vancomycin might be selected instead of nafcillin for methicillin-susceptible 
Staphylococcus aureus infections, or carbapenems might be avoided due to stability issues). 
The lack of healthcare provider supervision and coordinated care of patients receiving OPAT led 
to suboptimal patient care and serious adverse consequences on several occasions. The heightened 
need for coordinated care and quality assurance for patients receiving OPAT became evident as 
adverse outcomes caused by inadequate management of OPAT mounted. Institutional 
observations revealed multiple hospital readmissions and emergency department visits by patients 
receiving OPAT due to adverse events (e.g., nephrotoxicity, neutropenia), inadequate response to 
antibiotic therapy, or complications associated with vascular access devices that were not removed 
after the completion of therapy (e.g., endocarditis, pulmonary septic emboli). Among patients who 
developed endocarditis and septic pulmonary emboli due to retained vascular access devices, 
readmission and subsequent courses of therapy led to additional expenditures (in excess of $10,000 
per patient on average), which was especially noteworthy for patients enrolled in Health 
Advantage, who receive all of their care within the EH system, which is funded by county tax 
dollars. Many of the adverse events and readmissions may have been prevented with appropriate 
monitoring and management of OPAT. Therefore, the need for improvement in all of the 
aforementioned performance areas served as the basis for justification of the development of a 
formal OPAT program at EH. 
Program planning and development 
In 2005, a pharmacist-managed OPAT program, including a physician-staffed clinic, was proposed 
as a means to provide consistent and comprehensive care to patients requiring OPAT. The initial 
proposal highlighted the differences between OPAT practices at EH and the recommended 
practices outlined in the IDSA guidelines on OPAT. This information was presented at a meeting 
of the hospital’s anti-infective subcommittee for initial comment and approval and then presented 
to managers and directors within multiple departments (e.g., medical management, ID).  
During the process of planning for the OPAT program, it was recognized that it would be best to 
outsource the home infusion services to a home care agency. But the outsourcing of home infusion 
services for Health Advantage–eligible patients would lead to increased direct costs associated 
with nurse visits, laboratory monitoring, and care coordination. However, based on a 
comprehensive analysis of the costs of managing avoidable OPAT complications, it was 
determined that the improved care provided by a formal OPAT program would ultimately decrease 
overall OPAT-associated costs by preventing complications stemming from inadequate 
monitoring (e.g., line-related complications due to retained vascular access devices). The planning 
group decided that outsourcing the home infusion services to a home care agency would (1) expand 
the selection of antimicrobial agents available for OPAT to include those delivered via state-of-
the-art infusion devices and drug delivery systems, (2) allow for nurse home visits for the purposes 
of blood sampling for laboratory monitoring, i.v. line site evaluation and dressing changes, 
infection assessment, and compliance assessment, and (3) enable continuous monitoring 
throughout the course of therapy.  
Pursuant to a review of feedback from stakeholders regarding the initial proposal, a final OPAT 
program proposal was developed by the hospital’s ID clinical pharmacist and ID physicians in 
September 2007. The proposal included (1) descriptions of deviations in existing OPAT services 
from the IDSA guideline on OPAT recommendations, (2) an OPAT program policy and procedure 
outlining the process for OPAT patient assessment, evaluation, and monitoring, (3) a report 
describing recently observed complications in OPAT patients with retained vascular access 
devices and the associated costs, (4) annual estimates of the number of Health Advantage–eligible 
patients who would require OPAT and cost projections for providing coordinated OPAT services, 
and (5) a cost analysis by local home infusion service providers of commonly used antibiotic 
regimens and services (this was important because the OPAT program would require that outside 
vendors provide medications, supplies, and nurse visits for patients eligible for Health Advantage). 
The OPAT proposal was formally presented to the anti-infective subcommittee, the pharmacy and 
therapeutics committee, and the hospital administration; it was approved and implemented on July 
1, 2008. 
OPAT program process 
An algorithm (Figure 1) describing the process for OPAT patient evaluation, selection, and 
monitoring at EH was developed jointly by the ID department and the departments of pharmacy 
and transition support (medical management) using the IDSA guidelines on OPAT.1 According to 
a quality mandate set forth by the hospital administration to assure appropriate patient selection 
for OPAT, the primary medical or surgical team must contact the inpatient ID consultation service 
for review and approval of OPAT before discharge. In addition, a vascular access device for the 
purpose of administering OPAT cannot be placed unless recommended by the ID service. The 
predischarge review of the patient (typically conducted by an ID physician and an ID pharmacist) 
can be in the form of either a brief review of the medical record or a formal consultation by the 
inpatient ID consult team with the latter typically employed in difficult cases that require extensive 
medical record review and physical examination. Simultaneously, the social worker or case 
manager evaluates the patient’s insurance coverage, home or living situation, social history 
(including use of illicit substances), willingness and ability to administer OPAT, and caregiver 
support in order to determine the feasibility of OPAT. Appropriate patient selection is integral to 
the successful and safe use of OPAT, which is best utilized in patients who have infections 
requiring parenteral antimicrobial therapy, who are medically stable and in whom the risk of 
sudden life-threatening changes in health is minimal, who have a clean and safe home or outpatient 
environment for the administration of parenteral antimicrobial agents, and who are willing to 
participate and comply with all aspects of care (Figure 2). Lastly, in the EH program it is 
recommended that patients with a recent history of intravenous illicit drug use receive OPAT in a 
supervised setting (e.g., skilled nursing facility, infusion clinic) due to the risk of noncompliance 
and possible abuse of the vascular access device. 
Figure 1  
Flow chart of outpatient parenteral antimicrobial therapy (OPAT) process at Eskenazi Health. ID = infectious diseases, 
PICC = peripherally inserted central catheter. Asterisks denote simultaneous activities. If the patient has a current or 
recent history of i.v. drug abuse, administration of i.v. antibiotics in a supervised setting (skilled nursing facility), daily 
intramuscular injections, or daily infusions (with daily removal of the catheter) is advised.  
 
 
If OPAT is deemed appropriate for a patient, an inpatient ID physician or pharmacist approves the 
placement of the vascular access device (a peripherally inserted central catheter [PICC], a midline 
catheter, or a peripheral catheter, depending on the expected duration of OPAT) and documents 
an overall OPAT plan of care using a template (Figure 3) in the hospital’s electronic medication 
order-entry system. The OPAT template outlines (1) the indication(s) for parenteral antibiotic 
therapy, (2) the recommended antibiotic(s), dose(s), and frequency of administration, (3) the 
tentative therapy completion date, (4) specific laboratory values to be monitored and the 
monitoring frequency, (5) the fax number for transmittal of laboratory test results, (6) contact 
information for OPAT program personnel, and (7) details of OPAT clinic follow-up appointments, 
if applicable. After the patient’s discharge from the hospital, an OPAT team member (usually the 
OPAT pharmacist, the social worker, or the case manager) confirms the antibiotic, laboratory, and 
OPAT clinic orders with the accepting facility or home care agency. If OPAT is not approved by 
the inpatient ID team, alternative recommendations (e.g., conversion to oral therapy, 
discontinuation of antibiotic therapy) are provided. 
Figure 2  
Outpatient parenteral antimicrobial therapy (OPAT) patient selection algorithm used by Eskenazi Health. ID = infectious diseases. 
 
 
Once the patient is discharged, members of the OPAT team provide oversight of all aspects of 
outpatient antiinfective use for the entire course of therapy, including therapeutic drug monitoring 
and dosage adjustment, monitoring of laboratory results and the occurrence of adverse effects, 
evaluation and resolution of line-related complications, monitoring of response to therapy, and 
ensuring that therapy is completed within the specified timeframe, with subsequent removal of the 
vascular access device. The majority of these daily functions are performed by the OPAT clinical 
pharmacist according to an OPAT scope of practice document that delineates the services provided 
by the pharmacist on behalf of the OPAT physician (appendix). In addition, most patients 
discharged with orders for OPAT (regardless of setting) are scheduled to see the OPAT physician 
on an outpatient basis for evaluation of response to therapy and assessment of treatment-related 
adverse events and line-related complications. In order to provide this follow-up care, the OPAT 
clinic was established as a half-day, once-weekly clinic staffed by an ID physician and the OPAT 
pharmacist, with the intent of adding clinic time and space, if needed, based on patient volume. 
Because the OPAT clinic was established within the EH medicine clinic, each examination room 
or work area was already equipped with needed supplies, with existing clerical, nursing, and 
ancillary staff available to assist with OPAT clinic activities. The nurse who was assigned to the 
OPAT clinic received hospital-based training on the care and removal of PICC and midline 
catheters. Lastly, to enhance patient monitoring and acquisition of quality-assurance data, a 
consultant was hired to create an electronic OPAT database (Microsoft Access, Microsoft 
Corporation, Redmond, WA) accessible from the hospital intranet. 
Figure 3  
Sample template for predischarge note in medical record outlining established plan of care for patient receiving outpatient parenteral 
antimicrobial therapy.  
 
Pharmacist duties and responsibilities 
The responsibilities of individual team members within an OPAT program have been described 
elsewhere.1 Unlike other OPAT programs described to date, the OPAT program at EH is a 
pharmacist-managed program, with expanded responsibilities for the OPAT pharmacist. This 
pharmacist serves as the codirector of the program and also as the inpatient ID clinical pharmacist 
responsible for daily patient rounds with the inpatient ID consult team. Therefore, the pharmacist 
assists with all aspects of OPAT before and after discharge, including appropriate patient selection; 
the selection of antimicrobial agents and doses; coordination and development of monitoring 
plans; predischarge patient education on the anticipated plan of care, potential adverse effects, and 
monitoring requirements; continuous patient monitoring; provision of clinical pharmacy services 
throughout the course of OPAT (under the protocol and scope of practice described in the 
appendix); ensuring the appropriate duration of OPAT and removal of the vascular access device; 
documentation of patient visits and changes to the plan in the OPAT database and medical record; 
and continuous communication with physicians regarding individual patient care issues and overall 
program quality-assurance issues. When the patient arrives for each OPAT clinic visit, the 
pharmacist conducts an interview using a standardized questionnaire (Figure 4) to obtain a 
comprehensive medication history, evaluate compliance with the OPAT regimen, determine the 
presence of treatment-related adverse effects or complications associated with the vascular access 
device, and assess the current status of the infection. Once the patient has been evaluated by the 
physician, the physician and the pharmacist discuss the patient’s progress and the potential need 
for changes to the OPAT plan of care. This information is then documented in the OPAT database 
and the electronic medical record. If changes are made to the established OPAT plan of care, the 
pharmacist communicates the changes to the home infusion company or skilled nursing facility. 
Figure 4  
Medication reconciliation and patient interview form used by pharmacists at Eskenazi Health’s outpatient parenteral antimicrobial 
therapy (OPAT) clinic. PICC = peripherally inserted central catheter.  
 
Discussion 
The primary goals of establishing the pharmacy-managed OPAT program at EH were to assure 
appropriate patient selection and provide enhanced oversight and quality of care for patients 
discharged with orders for OPAT. The success of this type of OPAT program and the subsequent 
improvement in patient care are highly dependent on a good working relationship between ID 
physicians and pharmacists, who must collaborate to make complex decisions integrating 
laboratory results, physical examination findings, radiographic findings, and home care 
assessments to improve the care of each patient. Pharmacist responsibilities are performed under 
a collaborative agreement with the ID physician, who is ultimately responsible for the overall care 
of the patient.  
As part of a performance-improvement initiative, the clinical outcomes, adverse effects, and line 
complications experienced by patients in the EH OPAT program are continuously evaluated. 
During the period July 1, 2008–January 14, 2010, 203 patients received OPAT for a mean duration 
of 34 days (range, 4–94 days).21 The main clinical indications for OPAT included osteomyelitis (n 
= 77, 38% of cases), skin and soft tissue infections (n = 47, 23%), bacteremia (n = 26, 13%), and 
septic arthritis (n = 16, 8%). Clinical cure (assessed at the end of the prescribed OPAT course) was 
achieved in 93% of patients. Adverse drug events necessitated a change in therapy in 6% of 
patients and hospitalization in 2% of patients. Line complications necessitated a change in therapy 
in 2% of patients and hospitalization in 5% of patients. The vascular access line was removed in 
97% of evaluable treatment courses at the completion of OPAT, with 3 patients requiring retention 
of the i.v. access device at the request of the primary physician. In addition, the formal OPAT 
program at EH has decreased costs and unnecessary usage of both oral and intravenous 
antimicrobials through the use of mandatory ID service review and approval of all OPAT 
courses.22 Overall, the OPAT program appears to be safe and effective for the management of 
patients with a variety of infections.  
Through organized planning and a collaborative interprofessional effort, a pharmacist-managed 
OPAT program was developed and implemented at a large county teaching hospital; the program 
can serve as a model for other healthcare systems.  
Conclusion 
The OPAT program provides structured monitoring, patient followup, and led to improvements in 
patient outcome with minimization of treatment and line-related adverse events. 
Appendix Sample protocol and scope of practice for pharmacist-managed outpatient 
parenteral antimicrobial therapy 
Drug Therapy Management Protocol for Patients Receiving Outpatient Parenteral Antimicrobial Therapy 
(OPAT) 
This drug therapy management protocol was developed to establish drug therapy management (DTM) by a 
pharmacist under a physician-initiated written protocol for patients being followed by the Outpatient Parenteral 
Antimicrobial Therapy (OPAT) Program who are receiving outpatient parenteral antimicrobial therapy at home, in a 
skilled nursing facility, in prison, or at an infusion center. The procedures, protocols, practices, and other items 
contained within these documents are intended to be guidelines for the pharmacists and physicians of this institution. 
In no instance should the contents of these documents be considered as standards of professional practice or as rules 
of conduct or for the benefit of any third party. The documents herein are guidelines only, and allow for professional 
discretion and deviation where the individual healthcare provider deems variation to be appropriate.  
A. At the time of approval of this protocol, the individual physicians authorized to prescribe drugs and 
responsible for the delegation of DTM for OPAT are [insert names]. This protocol shall not be affected by 
changes to the preceding list of physicians. However, physicians joining the OPAT team shall be provided 
a copy of this protocol.  
B. The clinical pharmacists who will implement the DTM for OPAT patients as delegated under this DTM 
protocol include [insert names].  
C. In accordance with the incorporated OPAT treatment guidelines, attached as [reference Exhibit A], the 
clinical pharmacist may provide care for patients in the OPAT program under this DTM protocol, to 
include:  
1. Assessment of the therapeutic needs of each patient receiving outpatient parenteral antimicrobial 
therapy for the treatment of an infection on behalf of [insert physician name(s)]. Disease 
states/infections include but are not limited to cellulitis, osteomyelitis, diabetic foot infections, 
urinary tract infections, pyelonephritis, endocarditis, meningitis, brain abscess, liver abscess, 
peritonitis, lung abscess, pneumonia, bacteremia, line infections, and vascular graft infections.  
2. Evaluation of pharmacologic and non-pharmacologic treatment regimens. 
3. Ordering and interpretation of pertinent laboratory studies. 
4. In accordance with pharmacologic privileges, attached as [reference Exhibit B], performance of 
drug evaluation, drug utilization review, and drug regimen review; and participation in the 
selection of antimicrobial agents (including initiation, renewal, and dosage adjustment pursuant to 
pharmacist’s level of privileges and treatment guidelines).  
5. Provision of patient education regarding disease state(s)/infection, pharmacologic, and non-
pharmacologic therapy, including the schedule for lab monitoring and potential adverse effects.  
6. Documentation of patient visits, patient care, and treatment decisions in the OPAT database and 
medical record, when necessary. The referring physician will have access to the OPAT database 
and all medical records.  
7. Consultation with referring physician and other members of the health care team, as appropriate, 
to include ancillary services (podiatry, dietary, social work, etc.), general medicine, orthopedics, 
and general surgery. Other subspecialty medicine consults will be in consultation with the 
referring physician.  
8. Obtain authorization from the physician for deviations from the treatment guidelines. 
9. The schedule for physician review of DTM and status reports of the patient to the physician will 
be based on the clinical condition and tolerance of recommended outpatient therapy of each 
individual patient. The services provided to the patient by the pharmacist will be conveyed 
verbally on a weekly basis, during each clinic visit, and on an as needed basis. A supervising 
physician will also meet on a periodic basis with the clinical pharmacist to review the DTM 
protocol and patient care.  
10. This protocol does not delegate diagnosis or prescription to the clinical pharmacist. 
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